The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study.
Saved in:
| Title: | The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study. |
|---|---|
| Authors: | Li, Hongxin1 (AUTHOR), Zhao, Wen2 (AUTHOR), Li, Chengming3 (AUTHOR), Shen, Hongchang4 (AUTHOR), Li, Meiying5 (AUTHOR), Wang, Chengjun2 (AUTHOR), Han, Chunyan6,7 (AUTHOR), Yi, Cuihua2 (AUTHOR), Wang, Jun8,9 (AUTHOR), Meng, Xue3 (AUTHOR), Liu, Lian2 (AUTHOR), Yu, Shuwen10,11 (AUTHOR), Li, Jisheng2 (AUTHOR) lijisheng@sdu.edu.cn |
| Source: | Thoracic Cancer. Nov2024, Vol. 15 Issue 32, p2327-2338. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
